Sang T Kim1, Xerxes Pundole2, Ramona Dadu3, Olivier Lambotte4,5, Manuel Ramos-Casals6,7,8, Maria E Suarez-Almazor1,2. 1. Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 3. Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4. AP-HP. Université Paris-Saclay, Hôpital Bicêtre Department of Internal Medicine & Clinical Immunology, Le Kremlin Bicêtre, France. 5. Université Paris-Saclay; INSERM; CEA, Centre Immunology of Viral Infections & Autoimmune Diseases, IDMIT Department, IBFJ, Le Kremlin-Bicêtre, France. 6. Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Spain. 7. Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain. 8. Department of Medicine, University of Barcelona, Barcelona, Spain.
Abstract
Aim: To evaluate adverse events in cancer patients with pre-existing sarcoidosis receiving immune checkpoint inhibitors (ICIs). Patients & methods: We retrospectively reviewed cancer patients with sarcoidosis who underwent treatment with ICI to determine frequency of sarcoidosis flares. Results: 32 patients with sarcoidosis received ICIs The median time to ICI initiation was 7 years (range: 1 month to 51 years). One patient (3%) with a 20-year remote history of sarcoidosis developed a clinically symptomatic exacerbation after three doses of atezolizumab, with hilar lymphadenopathy, subcutaneous nodules, arthritis and uveitis. Atezolizumab was discontinued and prednisone initiated. She had a fluctuating course with two additional flares. Conclusion: Frequency of flares in patients with a remote history of sarcoidosis who receive ICIs is low.
Aim: To evaluate adverse events in cancer patients with pre-existing sarcoidosis receiving immune checkpoint inhibitors (ICIs). Patients & methods: We retrospectively reviewed cancer patients with sarcoidosis who underwent treatment with ICI to determine frequency of sarcoidosis flares. Results: 32 patients with sarcoidosis received ICIs The median time to ICI initiation was 7 years (range: 1 month to 51 years). One patient (3%) with a 20-year remote history of sarcoidosis developed a clinically symptomatic exacerbation after three doses of atezolizumab, with hilar lymphadenopathy, subcutaneous nodules, arthritis and uveitis. Atezolizumab was discontinued and prednisone initiated. She had a fluctuating course with two additional flares. Conclusion: Frequency of flares in patients with a remote history of sarcoidosis who receive ICIs is low.
Authors: Adrienne M Luoma; Shengbao Suo; Hannah L Williams; Tatyana Sharova; Keri Sullivan; Michael Manos; Peter Bowling; F Stephen Hodi; Osama Rahma; Ryan J Sullivan; Genevieve M Boland; Jonathan A Nowak; Stephanie K Dougan; Michael Dougan; Guo-Cheng Yuan; Kai W Wucherpfennig Journal: Cell Date: 2020-06-29 Impact factor: 41.582
Authors: Michael D Richter; Olga Pinkston; Lisa A Kottschade; Heidi D Finnes; Svetomir N Markovic; Uma Thanarajasingam Journal: Arthritis Rheumatol Date: 2018-02-06 Impact factor: 10.995
Authors: Katharina C Kähler; Thomas K Eigentler; Anja Gesierich; Lucie Heinzerling; Carmen Loquai; Friedegund Meier; Frank Meiss; Claudia Pföhler; Max Schlaak; Patrick Terheyden; Kai M Thoms; Mirjana Ziemer; Lisa Zimmer; Ralf Gutzmer Journal: Cancer Immunol Immunother Date: 2018-02-27 Impact factor: 6.968
Authors: Stacey N Harbour; Daniel F DiToro; Steven J Witte; Carlene L Zindl; Min Gao; Trenton R Schoeb; Gareth W Jones; Simon A Jones; Robin D Hatton; Casey T Weaver Journal: Sci Immunol Date: 2020-07-17
Authors: Radha Ramesh; Lina Kozhaya; Kelly McKevitt; Ivana M Djuretic; Thaddeus J Carlson; Maria A Quintero; Jacob L McCauley; Maria T Abreu; Derya Unutmaz; Mark S Sundrud Journal: J Exp Med Date: 2014-01-06 Impact factor: 14.307
Authors: Florentia Dimitriou; Anna L Frauchiger; Mirjana Urosevic-Maiwald; Mirjam C Naegeli; Simone M Goldinger; Marjam Barysch; Daniel Franzen; Jivko Kamarachev; Ralph Braun; Reinhard Dummer; Joanna Mangana Journal: Melanoma Res Date: 2018-06 Impact factor: 3.599